Loading...

Simavita

ASX:SVA
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SVA
ASX
A$7M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Simavita Limited develops medical devices for the assessment and management of urinary incontinence in Australia, North America, and Europe. The last earnings update was 202 days ago. More info.


Add to Portfolio Compare Print
SVA Share Price and Events
7 Day Returns
0%
ASX:SVA
3.2%
AU Medical Equipment
-0%
AU Market
1 Year Returns
30.8%
ASX:SVA
-2.2%
AU Medical Equipment
4.6%
AU Market
SVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Simavita (SVA) 0% 0% - 30.8% -62.2% -96.6%
AU Medical Equipment 3.2% -0.5% 0.8% -2.2% 38.7% 105%
AU Market -0% 1% 6.9% 4.6% 18.2% 4.8%
1 Year Return vs Industry and Market
  • SVA outperformed the Medical Equipment industry which returned -2.2% over the past year.
  • SVA outperformed the Market in Australia which returned 4.6% over the past year.
Price Volatility
SVA
Industry
5yr Volatility vs Market

Value

 Is Simavita undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Simavita is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Simavita has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Simavita. This is due to cash flow or dividend data being unavailable. The share price is A$0.017.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Simavita's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Simavita's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:SVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in AUD A$-0.02
ASX:SVA Share Price ** ASX (2019-02-22) in AUD A$0.02
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Simavita.

ASX:SVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:SVA Share Price ÷ EPS (both in AUD)

= 0.02 ÷ -0.02

-1.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Simavita is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Simavita is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Simavita's expected growth come at a high price?
Raw Data
ASX:SVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Simavita, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Simavita's assets?
Raw Data
ASX:SVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in AUD A$-0.01
ASX:SVA Share Price * ASX (2019-02-22) in AUD A$0.02
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:SVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:SVA Share Price ÷ Book Value per Share (both in AUD)

= 0.02 ÷ -0.01

-2.98x

* Primary Listing of Simavita.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Simavita has negative assets, we can't compare the value of its assets to the AU Medical Equipment industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Simavita's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Medical Equipment industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Simavita's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Simavita has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Simavita expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Simavita has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Simavita expected to grow at an attractive rate?
  • Unable to compare Simavita's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Simavita's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Simavita's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:SVA Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:SVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:SVA Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-06-30 0 -4 -5
2018-03-31 1 -5 -5
2017-12-31 1 -5 -6
2017-09-30 1 -4 -7
2017-06-30 1 -6 -8
2017-03-31 1 -7 -9
2016-12-31 1 -8 -10
2016-09-30 1 -11 -11
2016-06-30 1 -12 -11
2016-03-31 1 -12 -12
2015-12-31 1 -10 -11
2015-09-30 1 -9 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Simavita is high growth as no earnings estimate data is available.
  • Unable to determine if Simavita is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:SVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Simavita Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:SVA Past Financials Data
Date (Data in AUD Millions) EPS *
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.02
2017-06-30 -0.03
2017-03-31 -0.04
2016-12-31 -0.05
2016-09-30 -0.08
2016-06-30 -0.10
2016-03-31 -0.12
2015-12-31 -0.13
2015-09-30 -0.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Simavita will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Simavita's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. Simavita's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Simavita's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Simavita has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Simavita performed over the past 5 years?

  • Simavita's last earnings update was 202 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Simavita's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Simavita does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Simavita's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Simavita's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Simavita's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Simavita Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:SVA Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.41 -4.94 4.39 1.21
2018-03-31 0.54 -5.40 4.94 1.29
2017-12-31 0.67 -5.85 5.50 1.37
2017-09-30 0.74 -6.55 6.34 1.48
2017-06-30 0.91 -7.75 7.76 1.57
2017-03-31 0.94 -8.64 9.02 1.82
2016-12-31 0.89 -10.15 10.22 2.21
2016-09-30 0.86 -11.23 10.95 2.50
2016-06-30 0.79 -11.46 11.04 2.71
2016-03-31 0.69 -12.18 11.20 2.84
2015-12-31 0.67 -11.11 10.48 2.55
2015-09-30 0.88 -9.78 9.79 2.56
2015-06-30 0.78 -9.46 9.20 2.45
2015-03-31 0.71 -7.05 7.12 2.24
2014-12-31 0.66 -9.25 7.32 2.25
2014-09-30 0.37 -10.50 7.04 2.01
2014-06-30 0.35 -10.49 6.32 2.02
2014-03-31 0.29 -10.62 6.67 1.99
2013-12-31 0.29 -8.87 6.11 2.01
2013-09-30 0.30 -7.82 5.71 1.88
2013-06-30 0.32 -7.39 5.86 1.72
2012-06-30 0.70 -6.95 6.26 2.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Simavita has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Simavita has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Simavita improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Simavita's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Simavita has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Simavita's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Simavita's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Simavita's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Simavita's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Simavita's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Simavita has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Simavita Company Filings, last reported 9 months ago.

ASX:SVA Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -1.77 3.53 1.36
2018-03-31 -1.77 3.53 1.36
2017-12-31 0.59 1.35 1.71
2017-09-30 0.59 1.35 1.71
2017-06-30 3.10 0.00 2.07
2017-03-31 3.10 0.00 2.07
2016-12-31 4.22 0.00 3.35
2016-09-30 5.89 0.00 3.50
2016-06-30 7.65 0.00 6.17
2016-03-31 3.20 0.00 1.99
2015-12-31 4.62 0.00 2.42
2015-09-30 7.67 0.00 6.10
2015-06-30 10.19 0.00 9.07
2015-03-31 5.14 0.00 4.22
2014-12-31 7.28 0.00 5.00
2014-09-30 8.90 0.00 7.72
2014-06-30 7.53 0.00 6.87
2014-03-31 6.00 0.00 5.88
2013-12-31 8.01 0.00 7.92
2013-09-30 -1.12 2.54 0.33
2013-06-30 -8.59 10.15 0.75
2012-06-30 -1.04 3.73 1.48
  • Simavita has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Simavita's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Simavita has less than a year of cash runway based on current free cash flow.
  • Simavita has less than a year of cash runway if free cash flow continues to reduce at historical rates of -31.3% each year.
X
Financial health checks
We assess Simavita's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Simavita has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Simavita's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Simavita dividends.
If you bought A$2,000 of Simavita shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Simavita's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Simavita's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:SVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Simavita has not reported any payouts.
  • Unable to verify if Simavita's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Simavita's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Simavita has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Simavita's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Simavita afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Simavita has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Simavita's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Simavita has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the Simavita management team in years:

3.5
Average Tenure
  • The tenure for the Simavita management team is about average.
Management Team

Peter Curran

TITLE
Chief Technology Officer
COMPENSATION
A$298K
TENURE
4.9 yrs

Peta Jurd

TITLE
Chief Commercial Officer & Company Secretary
COMPENSATION
A$340K
TENURE
3.6 yrs

Wessel Dijk

TITLE
Vice President of Europe Sales & Marketing
COMPENSATION
A$342K
TENURE
3.4 yrs

Emma Lawler

TITLE
Co-Company Secretary
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure of the Simavita board of directors in years:

3
Average Tenure
  • The tenure for the Simavita board of directors is about average.
Board of Directors

Michael Spooner

TITLE
Non-Executive Chairman
COMPENSATION
A$150K
AGE
61
TENURE
3 yrs

Damien Haakman

TITLE
Non-Executive Director
TENURE
0.3 yrs

Joseph Ouslander

TITLE
Member of Clinical & Scientific Advisory

David Fonda

TITLE
Member of Clinical & Scientific Advisory

Sue Macri

TITLE
Member of Clinical & Scientific Advisory

Alan Cottenden

TITLE
Member of Clinical & Scientific Advisory

Gary Pace

TITLE
Non-Executive Director
COMPENSATION
A$100K
AGE
70
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Simavita's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Simavita has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Why Simavita Limited's (ASX:SVA) Investor Composition Impacts Your Returns

In this analysis, my focus will be on developing a perspective on Simavita Limited’s (ASX:SVA) latest ownership structure, a less discussed, but important factor. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … ASX:SVA Ownership Summary August 3rd 18

Simply Wall St -

Who Owns Simavita Limited (ASX:SVA)?

In this article, I'm going to take a look at Simavita Limited’s (ASX:SVA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … Thus, investors should dig deeper into SVA's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: SVA's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Should You Buy Simavita Limited (ASX:SVA) For This Reason?

Cash is crucial to run a business, and if a company burns through its reserves fast, it will need to come back to market for additional capital raising. … The measure of how fast Simavita goes through its cash reserves over time is called the cash burn rate. … ASX:SVA Income Statement May 24th 18 When will Simavita need to raise more cash?

Simply Wall St -

Did Simavita Limited's (ASX:SVA) Recent Earnings Growth Beat The Trend?

For the most up-to-date info, I use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … Eyeballing growth from a sector-level, the Australian medical equipment industry has been enduring some headwinds in the previous year, leading to an average earnings drop of -3.23%. … This means that although Simavita is currently loss-making, whatever recent headwind the industry is enduring, Simavita is relatively better-cushioned than its peers.What does this mean?

Simply Wall St -

Should You Be Concerned About Simavita Limited's (ASX:SVA) Shareholders?

Today, I will be analyzing Simavita Limited’s (ASX:SVA) recent ownership structure, an important but not-so-popular subject among individual investors. … Check out our latest analysis for Simavita ASX:SVA Ownership_summary Feb 28th 18 Institutional Ownership In SVA's case, institutional ownership stands at 15.66%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: SVA's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

When Will Loss-Maker Simavita Limited (ASX:SVA) Need More Cash?

The single most important question to ask when you’re investing in a loss-making company is – will they need to raise cash again, and if so, when? … Looking at Simavita’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … ASX:SVA Income Statement Feb 20th 18 When will Simavita need to raise more cash?

Simply Wall St -

Want To Invest In Simavita Limited (ASX:SVA)? Here's How It Performed Lately

Check out our latest analysis for Simavita Could SVA beat the long-term trend and outperform its industry? … I use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … Eyeballing growth from a sector-level, the Australian medical equipment industry has been ramping up growth, more than doubling average earnings over the previous twelve months, and a strong 16.24% over the past couple of years.

Simply Wall St -

What Kind Of Risk And Return Should You Expect For Simavita Limited (ASX:SVA)?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … With a beta of 1.41, Simavita is a stock that tends to experience more gains than the market during a growth phase and also a bigger reduction in value compared to the market during a broad downturn. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

What Does Simavita Limited's (ASX:SVA) Ownership Structure Look Like?

Insider Ownership Another important group of shareholders are company insiders. … ASX:SVA Insider Trading Oct 20th 17 General Public Ownership The general public, with 5.97% stake, is also an important group of shareholders in SVA. … Private Company Ownership Potential investors in SVA should also look at another important group of investors: private companies, with a stake of 35.33%, who are primarily invested because of strategic and capital gain interests.

Simply Wall St -

Company Info

Description

Simavita Limited develops medical devices for the assessment and management of urinary incontinence in Australia, North America, and Europe. It offers AlertPLUS, a disruptive platform technology for the international diaper market that provides real time alerts giving peace of mind to parents and carers; and assessPLUS, a solution for the assessment and management of incontinence. The company is headquartered in North Sydney, Australia.

Details
Name: Simavita Limited
SVA
Exchange: ASX
Founded:
A$7,045,561
414,444,801
Website: http://simavita.com
Address: Simavita Limited
54 Miller Street,
Suite 2.02,
North Sydney,
New South Wales, 2060,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX SVA CDI NPV 1:1 Australian Securities Exchange AU AUD 20. Feb 2014
Number of employees
Current staff
Staff numbers
0
Simavita employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 10:35
End of day share price update: 2019/02/22 00:00
Last earnings filing: 2018/10/03
Last earnings reported: 2018/06/30
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.